Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients

• Published in: Annals of surgical oncology Vol. 30; no. 8; pp. 5239 - 5247
• Main Authors: Shinto, Eiji, Oki, Eiji, Shimokawa, Mototsugu, Yamaguchi, Shigeki, Ishiguro, Megumi, Hasegawa, Seiji, Takii, Yasumasa, Ishida, Hideyuki, Kusumoto, Tetsuya, Morita, Masaru, Tomita, Naohiro, Shiozawa, Manabu, Tanaka, Masafumi, Ozawa, Heita, Hashiguchi, Yojiro, Ohnuma, Shinobu, Tada, Sachiyo, Matsushima, Tomoko, Yamagishi, Keisuke, Hase, Kazuo
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2023; Springer Nature B.V
• Subjects: Cbfa-1 protein; Chemotherapy; Colon cancer; Colorectal cancer; Medicine; Medicine & Public Health; Oncology; Paraffin; Patients; Surgery; Surgical Oncology; Translational Research

Background A molecular budding signature (MBS), which consists of seven tumor budding-related genes, was recently presented as a prominent prognostic indicator in colon cancer (CC) using microarray data acquired from frozen specimens. This study aimed to confirm the predictive power of MBS for recur...